<!DOCTYPE html>
<html>
<head>

<style>
* {
  box-sizing: border-box;
}
body {
  margin: 0;
  font-family: "Lato", sans-serif;
  /*agregar color oscuro para el fondo*/
  background: #f1f1f1;
}
  /* Header/Logo Title */
.bg-image {
  /* The image used */
  background-image:url('bg.jpg');
  
  /* Add the blur effect */
  filter: blur(8px);
  -webkit-filter: blur(8px);
  
  /* Full height */
  height: 100%; 
  
  /* Center and scale the image nicely */
  background-position: center;
  background-repeat: no-repeat;
  background-size: cover;
}

/* Position text in the middle of the page/image */
.bg-text {
  background-color: rgb(0,0,0); /* Fallback color */
  background-color: rgba(0,0,0, 0.4); /* Black w/opacity/see-through */
  color: white;
  font-weight: bold;
  border: 3px solid #f1f1f1;
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  z-index: 2;
  width: 80%;
  padding: 20px;
  text-align: center;
}
.header {
  padding: 1px;
  text-align: center;
  background: linear-gradient(to bottom, 	#254666 30%, #4d667f 100%);
  color: white;
  font-size: 20px;
  margin-left: 200px;
} 
.center {
  display: block;
  margin-left: auto;
  margin-right: auto;
  width: 50%;
}
  .sidebar {
  margin: 0;  
  padding: 0;
  width: 200px;
  background-color: #FFFFFF;
  position: fixed;
  height: 100%;
  overflow: auto;
}
.sidebar a {
  display: block;
  color: black;
  padding: 16px;
  text-decoration: none;
} 
.sidebar a.active {
  background-color: #294e71;
  color: white;
}
.sidebar a:hover:not(.active) {
  background-color: #4d667f;
  color: white;
}

div.content {
  margin-left: 200px;
  padding: 1px 16px;
  height: 1000px;
}

@media screen and (max-width: 100px) {
  .sidebar {
    width: 100%;
    height: auto;
    position: relative;
  }
  .sidebar a {float: left;}
  div.content {margin-left: 0;}
}

@media screen and (max-width: 100px) {
  .sidebar a {
    text-align: center;
    float: none;
  }
}
  .card {
   background-color: white;
   padding: 20px;
   margin-top: 10px;
   margin-left: 230px;
   margin-right:30px;
   margin-bottom: 10px;
   box-shadow: 5px 5px 5px #888888;
}
  .table {
  font-family: arial, sans-serif;
  border-collapse: collapse;
  width: 100%;
}
td, th {
  border: 1px solid #dddddd;
  text-align: left;
  padding: 8px;
}

tr:nth-child(even) {
  background-color: #dddddd;
}
  
.column {
  float: left;
  width: 20%;
  padding: 0 10px;
}
.left {
  width: 60%;
}
.right {
  width: 40%;
}
/* Remove extra left and right margins, due to padding */
.row {margin: -5px -5px;
}
/* Clear floats after the columns */
.row:after {
  content: "";
  display: table;
  clear: both;
}
</style>
</head>
<body>

  
<div class="sidebar">
  <br>
  <img src="/media/Logo.jpg" alt="Logo" style="width:90%;max-width:500px" class="center">
  <a class="active" href="#1_about_us">About us</a>
  <a href="/2_research">Research</a>
  <a href="/3_publications">Publications</a>
  <a href="/4_members">Members</a>
  <a href="/5_join_us">Join us</a>
  <a href="/6_events">Events & News</a>
  <a href="/7_contact">Contact</a>
</div>
  
<div class="header">
  <h1>Ramírez Lab </h1>
  <p>Computational Biophysics, Bioinformatics & Drug Design</p>
  </div>


<div class="card">
  <h2>Welcome to the Ramírez Lab</h2>
  <div class="bg-image"></div>
  <p align="justify">We are a multidisciplinary group focusing on the study of biomolecular systems 
    by using both, computational and experimental approaches. We aim to use computational methods - broadening 
    the way to describe biology phenomena - to combine and use them together with wet lab analyses for 
    drug design and development processes. Our work involves collaboration with medicinal chemists, 
    biochemists, and biologists, and we are part of the Institute of Biomedical Sciences at Universidad 
    Autónoma de Chile.</p>
</div>
  
<div class="card">
  <h2><a href="/2_research">Active research areas</a></h2>
  <li align="justify">Structural insights into the substrate specificity and transport mechanisms in the Nitrate/Peptide Transporter (NPF) Family</li><br> 
  <li align="justify">Targeting cancer polypharmacology</li><br>
  <li align="justify">Promiscuous-drug design of molecules targeting neurodegenerative diseases</li><br>
  <li align="justify">Ion occupancy in potassium channels</li><br>
  <li align="justify">Unraveling the role of the side-fenestration in ion channels gating</li><br>  
  <li align="justify">Understanding the binding mechanisms of endo and phytocannabinoids into the human CB1 receptor</li><br>
</div>

<div class="card">
  <h2><a href="/3_publications">Latest publication</a></h2>
       <h3><a href="https://www.mdpi.com/1422-0067/20/16/4014">Discovery of Novel TASK-3 Channel Blockers Using a Pharmacophore-Based Virtual Screening</a></h3>
       <h5>David Ramírez, Guierdy Concha, Bárbara Arévalo, Luis Prent-Peñaloza, Leandro Zúñiga, Aytug K. Kiper, Susanne Rinné, Miguel Reyes-Parada, Niels Decher, Wendy González, and Julio Caballero</h5>
   <p>International Journal of Molecular Sciences, 2019, doi: 10.3390/ijms20164014</p>
      <div class="row">
      <div class="column left">
      <p align="justify">TASK-3 is a two-pore domain potassium (K2P) channel highly expressed in the hippocampus, 
        cerebellum, and cortex. TASK-3 has been identified as an oncogenic potassium channel and it is overexpressed 
        in different cancer types. For this reason, the development of new TASK-3 blockers could influence the 
        pharmacological treatment of cancer and several neurological conditions. In the present work, we searched for 
        novel TASK-3 blockers by using a virtual screening protocol that includes pharmacophore modeling, molecular 
        docking, and free energy calculations. With this protocol, 19 potential TASK-3 blockers were identified. 
        These molecules were tested in TASK-3 using patch clamp, and one blocker (DR16) was identified with an 
        IC50 = 56.8 ± 3.9 μM. Using DR16 as a scaffold, we designed DR16.1, a novel TASK-3 inhibitor, with an 
        IC50 = 14.2 ± 3.4 μM. Our finding takes on greater relevance considering that not many inhibitory 
        TASK-3 modulators have been reported in the scientific literature until today. These two novel 
        TASK-3 channel inhibitors (DR16 and DR16.1) are the first compounds found using a pharmacophore-based 
        virtual screening and rational drug design protocol.</p>
      </div> 
      <div class ="column right">
      <img src="/media/DR16_Graphical-abstract.png" style="width:100%">
      </div></div>
</div>  

  
 
<div class="card">
  <h2>Funding</h2>
  <table>
  <tr>
    <th>Grant</th>
    <th>Funded by</th>
    <th>Role</th>
    <th>Date</th>
  </tr>
  <tr>
    <td>Multi-Target Drug Design Against Neurodegenerative Diseases.</td>
    <td>Conicyt No. REDES190074</td>
    <td>Principal Investigator</td>
    <td>2020 - 2021</td>
  </tr>
  <tr>
    <td>INSECTR – International Network to Study Secondary Metabolite Transport In Plants.</td>
    <td>Conicyt No. REDES1900254</td>
    <td>Associate Investigator</td>
    <td>2020 - 2021</td>
  </tr>
  <tr>
    <td>Identificación de reacciones controladoras de lipotoxicidad inducida por ácido palmítico en un modelo computacional multiómico astrocitario.</td>
    <td>Colciencias No. 67270 (Colombia)</td>
    <td>Co-investigator</td>
    <td>2020 - 2021</td>
  </tr>   
  <tr>
    <td>Scholarship Programme for Young Professors and Researchers from Latin American Universities.</td>
    <td>Coimbra group</td>
    <td>Principal Investigator</td>
    <td>2019</td>
  </tr>
  <tr>
    <td>Structural insights into the substrate specificity and transport mechanisms in the Nitrate/Peptide Transporter (NPF) Family.</td>
    <td>Fondecyt No. 11180604</td>
    <td>Principal Investigator</td>
    <td>2018 – 2021</td>
  </tr>
  <tr>
    <td>Análisis metabolómico de los efectos neuroprotectores de la tibolona en un modelo astrocitico humano de lipotoxicidad con ácido palmítico.</td>
    <td>Colciencias</td>
    <td>International Advisor</td>
    <td>2017 - 2020</td>
  </tr>
</table>
</div>  

</body>
</html>
